Ascentage Pharma Group International said Chairman and CEO Dr. Dajun Yang has been named to The Medicine Maker Power List 2026, a recognition that places him among notable figures in the pharmaceutical and biotech sector. The company announced the news from Rockville, Maryland, and Suzhou, China.
Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies. The listing of Yang on the 2026 power list underscores his visibility within the industry as the company continues to expand its position in drug development and commercialization.
The announcement also draws attention to Ascentage Pharma's international footprint. The company is publicly traded on both Nasdaq under AAPG and the Hong Kong Stock Exchange under 6855, reflecting its cross-border presence in the biotech market.
While the release centers on Yang's inclusion in The Medicine Maker Power List 2026, it also highlights the broader momentum of Ascentage Pharma as it advances its business as an integrated biopharmaceutical company. The recognition adds to the company's profile at a time when leadership and execution remain closely watched across the global life sciences industry.
